These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 37023853)
21. Clinical value of therapeutic drug monitoring for levetiracetam in pediatric patients with epilepsy. Yamamoto Y; Ohta A; Usui N; Imai K; Kagawa Y; Takahashi Y Brain Dev; 2023 May; 45(5):285-292. PubMed ID: 36759254 [TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Rhee SJ; Shin JW; Lee S; Moon J; Kim TJ; Jung KY; Park KI; Lee ST; Jung KH; Yu KS; Jang IJ; Chu K; Lee SK Epilepsy Res; 2017 May; 132():8-14. PubMed ID: 28279893 [TBL] [Abstract][Full Text] [Related]
23. Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities. Toublanc N; Lacroix BD; Yamamoto J Drug Metab Pharmacokinet; 2014; 29(1):61-8. PubMed ID: 23877106 [TBL] [Abstract][Full Text] [Related]
24. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. Maharaj AR; Barrett JS; Edginton AN AAPS J; 2013 Apr; 15(2):455-64. PubMed ID: 23344790 [TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of levetiracetam in neonates with seizures. Lima-Rogel V; López-López EJ; Medellín-Garibay SE; Gómez-Ruiz LM; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S J Clin Pharm Ther; 2018 Jun; 43(3):422-429. PubMed ID: 29265480 [TBL] [Abstract][Full Text] [Related]
26. Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen. Tauzin M; Tréluyer JM; Nabbout R; Chemaly N; Billette de Villemeur T; Desguerre I; Lui G; Gana I; Boujaafar S; Zheng Y; Benaboud S; Bouazza N; Chenevier-Gobeaux C; Freihuber C; Hirt D J Clin Pharmacol; 2021 Oct; 61(10):1366-1375. PubMed ID: 33997989 [TBL] [Abstract][Full Text] [Related]
27. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations. Wang R; Wang T; Han X; Chen M; Li S Xenobiotica; 2024 Mar; 54(3):116-123. PubMed ID: 38344757 [TBL] [Abstract][Full Text] [Related]
28. Characterization of Pediatric Rectal Absorption, Drug Disposition, and Sedation Level for Midazolam Gel Using Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling. Zhu J; Zhou S; Wang L; Zhao Y; Wang J; Zhao T; Li T; Shao F Mol Pharm; 2024 May; 21(5):2187-2197. PubMed ID: 38551309 [TBL] [Abstract][Full Text] [Related]
29. Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children. Ince I; Dallmann A; Frechen S; Coboeken K; Niederalt C; Wendl T; Block M; Meyer M; Eissing T; Burghaus R; Lippert J; Willmann S; Schlender JF J Clin Pharmacol; 2021 Jun; 61 Suppl 1(Suppl 1):S70-S82. PubMed ID: 34185905 [TBL] [Abstract][Full Text] [Related]
30. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Toublanc N; Sargentini-Maier ML; Lacroix B; Jacqmin P; Stockis A Clin Pharmacokinet; 2008; 47(5):333-41. PubMed ID: 18399714 [TBL] [Abstract][Full Text] [Related]
31. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE Cancer Chemother Pharmacol; 2024 Aug; 94(2):297-310. PubMed ID: 38782791 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic Drug Monitoring of Levetiracetam in Select Populations. Jarvie D; Mahmoud SH J Pharm Pharm Sci; 2018; 21(1s):149s-176s. PubMed ID: 30096051 [TBL] [Abstract][Full Text] [Related]
33. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children. Zhou W; Johnson TN; Xu H; Cheung S; Bui KH; Li J; Al-Huniti N; Zhou D CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):475-83. PubMed ID: 27566992 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups. Liu XI; van den Anker JN; Burckart GJ; Dallmann A J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902 [TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data. Ito S; Yano I; Hashi S; Tsuda M; Sugimoto M; Yonezawa A; Ikeda A; Matsubara K Ther Drug Monit; 2016 Jun; 38(3):371-8. PubMed ID: 26913593 [TBL] [Abstract][Full Text] [Related]
36. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. Abduljalil K; Jamei M; Rostami-Hodjegan A; Johnson TN AAPS J; 2014 May; 16(3):568-76. PubMed ID: 24700271 [TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy. Li Y; Wang ML; Guo Y; Cao YF; Zhao MM; Zhao LM Br J Clin Pharmacol; 2023 Mar; 89(3):1152-1161. PubMed ID: 36260320 [TBL] [Abstract][Full Text] [Related]
38. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Johnson TN; Rostami-Hodjegan A Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354 [TBL] [Abstract][Full Text] [Related]
39. Review on the relevance of therapeutic drug monitoring of levetiracetam. Sourbron J; Chan H; Wammes-van der Heijden EA; Klarenbeek P; Wijnen BFM; de Haan GJ; van der Kuy H; Evers S; Majoie M Seizure; 2018 Nov; 62():131-135. PubMed ID: 30237016 [TBL] [Abstract][Full Text] [Related]
40. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach. Guimarães M; Vertzoni M; Fotaki N AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]